Weight Loss Peptides: Semaglutide, Tirzepatide, and Retatrutide Compared

In depth: Peptides for Weight Loss: The Complete 2026 Guide

Peptides for weight loss are now the main reason people come to this category, and the effectiveness of the GLP-1 class is not in dispute. Semaglutide, tirzepatide and retatrutide have produced mean body weight reductions of roughly 15, 21 and 24 percent in trials, figures with no precedent outside surgery. The questions worth spending time on are which one, by which route, and what happens afterwards.

The Three Major Weight Loss Peptides

Semaglutide, tirzepatide, and retatrutide are the three peptides dominating weight loss conversations right now. All three work through GLP-1 pathway activation (glucagon-like peptide-1), which affects hunger, satiety, and metabolism.

Semaglutide was first and is most studied. It works well and costs less than newer options.

Tirzepatide is more effective (dual GLP-1/GIP activation), costs slightly more, and is newer.

Retatrutide is cutting edge (triple GLP-1/GIP/glucagon activation), most expensive, and least studied in long-term real-world use.

All three are covered below with the trial numbers attached, so the comparison rests on measured outcomes rather than on impressions.

Semaglutide for Weight Loss

Wegovy's labeled titration for chronic weight management is a five-step monthly escalation:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Each step is held for four weeks, so the labeled approach reaches the 2.4 mg maintenance dose at week 17, not at week 13. The 1.7 mg step exists to improve tolerability.

Trial results: STEP 1 (Wilding et al., NEJM 2021) reported approximately 15% mean weight loss at 68 weeks on 2.4 mg weekly. The 12-to-16-week window of treatment usually corresponds to roughly 6-8% loss; the headline figures are full-trial endpoints over more than a year.

What the semaglutide data shows. In STEP 1, 2.4mg weekly produced a mean 14.9 percent body weight reduction over 68 weeks against 2.4 percent on placebo. Appetite suppression is typically strong and arrives within the first week or two, well before the scale reflects it. The recurring practical difficulty reported is the opposite of the usual one: eating enough, and enough protein, when hunger has been removed as a signal.

Cost: Usually $250-400 monthly depending on source and dose. See our guide on semaglutide cost without insurance for more affordable options.

Tirzepatide for Weight Loss

Mounjaro and Zepbound titrate in 2.5 mg steps every four weeks:

• Weeks 1-4: 2.5 mg weekly (initiation; not a maintenance dose)
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Week 21 onward: 15 mg weekly

Approved maintenance doses are 5, 10, or 15 mg weekly, the labeling supports stopping at 10 mg if it's working, or escalating further to 15 mg if needed for additional weight loss.

Trial results: SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean weight loss of approximately 15% on 5 mg, 19% on 10 mg, and 21% on 15 mg over 72 weeks. Tirzepatide produced larger mean loss than semaglutide in the head-to-head SURMOUNT trials.

What the tirzepatide data shows. SURMOUNT-1 produced a mean 20.9 percent reduction at 15mg over 72 weeks, and SURMOUNT-5 beat semaglutide head to head at 20.2 percent against 13.7 percent. The gastrointestinal burden during escalation is correspondingly higher, and the cost is higher at every route. For tolerability see tirzepatide side effects and for the week by week picture tirzepatide before and after.

Cost: Usually $350-500 monthly. Check our comprehensive tirzepatide cost guide for pricing details.

Retatrutide for Weight Loss

Retatrutide is the newest of the three major weight loss peptides. It's still in Phase 3 clinical trials but shows the most impressive preliminary results. The triple mechanism (GLP-1, GIP, and glucagon activation) targets appetite, nutrient absorption, and metabolism simultaneously.

Retatrutide's Phase 2 obesity trial (Jastreboff et al., NEJM 2023) used four target maintenance doses, with stepwise titration in the higher-dose arms:

• 1 mg weekly (low-dose arm, no escalation)
• 4 mg weekly (titrated from 2 mg)
• 8 mg weekly (titrated 2 → 4 → 8 mg)
• 12 mg weekly (titrated 2 → 4 → 8 → 12 mg)

Trial results at 48 weeks: approximately 8% mean weight loss on 1 mg, 17% on 4 mg, 23% on 8 mg, and 24% on 12 mg. Retatrutide is currently in Phase 3 (the TRIUMPH program); FDA approval is most likely 2027 or 2028. As of April 2026 it is not yet approved.

Timeline with retatrutide: Similar to tirzepatide but potentially steeper in months 2-3. Most users report faster initial results due to the triple mechanism. However, more pronounced side effects are common, especially at dose escalations.

Side effect profile: More intense nausea and food aversions compared to semaglutide and tirzepatide. Gastrointestinal effects are more common and may take longer to subside. See our retatrutide dosage guide for detailed protocols and side effect management.

Cost: $300-800 monthly (highest cost among the three, but improving availability). Availability is still limited, primarily through research programs and select telehealth providers.

Practical Comparison for Decision-Making

If you want proven results at lower cost: semaglutide.

If you want better results and can tolerate slightly more side effects: tirzepatide.

If you want the latest, potentially most effective option and cost isn't a constraint: retatrutide.

From vendors like Limitless Life Peptides, all three are increasingly available through telehealth channels.

Timeline and What to Expect

Month 1: Appetite drops noticeably. Weight comes off fast, maybe 8-12 pounds (mostly water and initial fat loss). Side effects (nausea, food aversions) peak this month.

Month 2: Continued weight loss at 2-4 pounds weekly. Side effects settle slightly. You've adapted to the appetite suppression.

Month 3: Weight loss continues but may slow to 1-3 pounds weekly as your body adapts. You're seeing visible changes in the mirror and clothes fitting differently.

Month 4+: Weight loss plateaus. You're losing slowly or maintaining. If you want to continue, calorie restriction beyond appetite suppression might be needed, or escalating to a higher dose if available.

Eating with Suppressed Appetite

This is the biggest challenge and the most important skill. When you're not hungry but need to eat, you have to be intentional. Check our guide on how to inject peptides and how to reconstitute peptides to ensure proper administration.

Practically, meals get smaller and need to get denser. A portion that used to be a starter becomes a full meal, so what goes into it matters more. Protein first at every meal is the standard advice, because on reduced stomach capacity whatever is eaten first is what actually gets eaten. Protein shakes are widely used to close the gap on days when solid food is unappealing.

The risk is undereating, which causes fatigue, muscle loss, and nutrient deficiency. Track your intake even if you don't feel hungry.

Protein is the variable that decides what the loss is made of. Roughly 1.2 to 1.6 grams per kilogram of body weight is the commonly cited target, and hitting it alongside resistance training is what prevents a meaningful share of the weight lost from being lean mass. Without both, roughly a quarter of the total tends to come from muscle.

Cost Comparison to Alternatives

• Weight loss surgery: $15,000-30,000, permanent changes, significant recovery.
• Gym membership, trainer, nutritionist: $200-500 monthly, requires discipline, slower results.
• Peptide weight loss therapy: $250-800 monthly, 15-24% weight loss in 12-16 weeks, appetite-based compliance.

For most people, the cost-to-results ratio of peptides is compelling.

Side Effects and Tolerability

• Nausea: Most common, especially at dose escalations. Usually fades by day 3-4. Eating smaller meals helps.
• Vomiting: Less common. Usually happens if you eat too much or the wrong foods right after injection.
• Food aversions: Certain foods become unappealing. This passes as you adjust.
• Fatigue: Some people report low energy, usually from undereating.
• Constipation or diarrhea: GLP-1 affects gut motility. Usually manageable with diet.

Most people find these tolerable given the results. The ones who quit usually do so because nausea is worse than expected or because they can't handle appetite suppression.

Long-Term Sustainability

This is the question everyone asks: what happens when you stop?

The honest answer: weight regain is common but not inevitable. People who developed good eating habits while on peptides often maintain weight loss. People who "diet down" with peptides expecting to return to old habits tend to regain. See our peptides before and after gallery for real examples of sustainable results.

The most useful way to frame this class is as a window rather than a cure. The appetite suppression creates a period in which portion control, higher protein and lower calorie eating are unusually easy to practise, and habits built in that window are what remain when the drug stops. SURMOUNT-4 is the reason this matters: participants who stopped regained about 14 percent of body weight over the following year, while those who continued lost a further 5.5 percent. These compounds substitute for an appetite signal rather than resetting one.

Some people use peptides cyclically. A few months on, a few months off. This keeps results going while managing cost and side effects.

From Pantheon Peptides and Apollo Peptide Sciences, both have seen long-term customer data. Sustained weight loss is achievable if you don't rely 100% on the peptide.

When These Peptides Aren't Right

The GLP-1 class carries a boxed warning for personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The concern stems from C-cell tumors observed in rodents and is specific to those carcinomas, not to thyroid hormone disorders like Hashimoto's or hypothyroidism. If MTC or MEN 2 runs in your family, the GLP-1 class is contraindicated; for other thyroid conditions, talk to your clinician.

If you're not willing to address eating habits while using peptides, you're wasting money. The peptide handles appetite suppression, but you still need to make intentional food choices.

If you're looking for a quick fix without lifestyle change, you'll regain weight when you stop. These work best combined with actual dietary improvements.

Real Expectation Setting

You won't wake up six-pack abs. You'll lose fat over weeks and months. You'll feel less hungry. You'll need to eat intentionally. Results will be visible by month 3-4.

This is one of the most effective weight loss tools available. It's not magic, and it's not effortless, but the results are real.